Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives $21.00 Consensus Target Price from Analysts

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have been assigned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $21.00.

Separately, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Atara Biotherapeutics in a report on Thursday, November 13th.

Insider Buying and Selling at Atara Biotherapeutics

In other news, CEO Anhco Nguyen sold 2,915 shares of the firm’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $13.19, for a total value of $38,448.85. Following the sale, the chief executive officer owned 64,974 shares in the company, valued at approximately $857,007.06. This trade represents a 4.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold 6,523 shares of company stock valued at $86,038 over the last three months. 4.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Atara Biotherapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Marshall Wace LLP bought a new position in shares of Atara Biotherapeutics during the 2nd quarter worth about $327,000. Mackenzie Financial Corp grew its position in Atara Biotherapeutics by 183.5% during the third quarter. Mackenzie Financial Corp now owns 63,816 shares of the biotechnology company’s stock worth $914,000 after buying an additional 41,302 shares in the last quarter. EcoR1 Capital LLC increased its stake in Atara Biotherapeutics by 7.7% during the first quarter. EcoR1 Capital LLC now owns 573,183 shares of the biotechnology company’s stock valued at $3,405,000 after acquiring an additional 41,049 shares during the period. Staley Capital Advisers Inc. raised its holdings in Atara Biotherapeutics by 60.0% in the 1st quarter. Staley Capital Advisers Inc. now owns 80,000 shares of the biotechnology company’s stock valued at $475,000 after acquiring an additional 30,000 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in Atara Biotherapeutics by 6.6% in the 3rd quarter. Vanguard Group Inc. now owns 203,438 shares of the biotechnology company’s stock valued at $2,915,000 after acquiring an additional 12,677 shares in the last quarter. 70.90% of the stock is currently owned by institutional investors and hedge funds.

Atara Biotherapeutics Price Performance

Shares of ATRA opened at $14.03 on Friday. The company has a market capitalization of $101.16 million, a PE ratio of 6.44 and a beta of 0.26. Atara Biotherapeutics has a one year low of $5.01 and a one year high of $18.70. The company’s fifty day moving average price is $13.83 and its 200 day moving average price is $11.23.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Wednesday, November 12th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.51. The company had revenue of $3.45 million for the quarter, compared to the consensus estimate of $2.74 million. Atara Biotherapeutics had a negative return on equity of 41.78% and a net margin of 15.40%. Analysts anticipate that Atara Biotherapeutics will post -10.39 earnings per share for the current year.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.